AVB Biotechnology was established in 2020 with the objective of conducting therapeutic development initiatives aimed at addressing the global challenge of the COVID-19 pandemic.
Our journey began with the realization that fever—perceived for centuries merely as a 'symptom of disease'—is, in fact, a thermodynamically driven biophysical restoration process orchestrated to preserve millions of years of mammalian homeostasis. This insight paved the way for elucidating the existence, underlying mechanisms, and operational principles of the intricate bioelectrical architecture that governs the biological and chemical systems of the mammalian organism. At this juncture, the foundations of biomimetic technology, which emulates this ancient and highly conserved system of nature, were laid. As a tangible outcome of this process, the Bioelectrical Epigenetic Programming (BEP) technology was actualized, initiating its scientific trajectory.
Specifically designed to address unmet medical needs, the translational journey of this technology—bridging biophysical reality with clinical solutions—continues alongside our dynamic team dedicated to developing innovative approaches.